Institute for Drug Safety Sciences, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, 6 Davis Drive, PO Box 12137, Research Triangle Park, NC 27709, USA.
Clin Liver Dis. 2020 Feb;24(1):49-60. doi: 10.1016/j.cld.2019.09.003. Epub 2019 Nov 1.
The DILI-sim Initiative is a public-private partnership using quantitative systems toxicology to build a model (DILIsym) capable of understanding and predicting liver safety liabilities in drug candidates. The effort has provided insights into mechanisms underlying dose-dependent drug-induced liver injury (DILI) and interpatient differences in susceptibility to dose-dependent DILI. DILIsym may be useful in identifying drugs capable of causing idiosyncratic hepatotoxicity. DILIsym is used to optimize interpretation of traditional and newer serum biomarkers of DILI. DILIsym results are considered in drug development decisions. In the future, it may be possible to use DILsym predictions to justify reduction in size of some clinical trials.
DILI-sim 计划是一个公私合作伙伴关系，利用定量系统毒理学来构建一个模型（DILIsym），能够理解和预测候选药物的肝安全性风险。该计划提供了对剂量依赖性药物引起的肝损伤（DILI）和个体对剂量依赖性 DILI 的易感性差异的潜在机制的深入了解。DILIsym 可能有助于识别可能导致特发性肝毒性的药物。DILIsym 用于优化对传统和新型 DILI 血清生物标志物的解释。DILIsym 的结果在药物开发决策中被考虑。在未来，可能有可能使用 DILsym 预测来证明某些临床试验规模的减少是合理的。
